Quick Answer
Iterum Therapeutics plc reported Cash and Equivalents of $24.12 million for fiscal year 2024.
Iterum Therapeutics plc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $24.12M | +297.4% |
| 2023 | $6.07M | -71.2% |
| 2022 | $21.09M | -23.2% |
| 2021 | $27.45M | +89.2% |
| 2020 | $14.51M | +202.2% |
| 2019 | $4.80M | -89.2% |
| 2018 | $44.55M | +425.1% |
| 2017 | $8.48M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.00M | -17.9% | -15.5% |
| June 30, 2025 | $13.03M | +161.8% | +3.0% |
| March 31, 2025 | $12.65M | +71.2% | -47.6% |
| December 31, 2024 | $24.12M | +297.4% | +80.0% |
| September 30, 2024 | $13.41M | +178.4% | +169.4% |
| June 30, 2024 | $4.98M | -63.8% | -32.7% |
| March 31, 2024 | $7.39M | -56.1% | +21.7% |
| December 31, 2023 | $6.07M | -71.2% | +26.1% |
- Iterum Therapeutics plc showed an increase of +297.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2024 period, Iterum Therapeutics plc’s cash and equivalents has grown by 184.3% (from $8.48 million to $24.12 million).
- The most recent figure is from Iterum Therapeutics plc’s fiscal year 2024 report (Form 10-K), filed with the SEC on February 7, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: